| Medical and Health Sciences | 2021-2025 | 343 | CN 35 | 99.93 |
| Biological Sciences | 2021-2025 | 310 | CN 119 | 99.69 |
| Radiology, Nuclear Medicine and Imaging | Lifetime | 487 | CN 9 | 98.78 |
| Molecular Biology | 2021-2025 | 153 | CN 68 | 99.41 |
| Oncology | 2021-2025 | 88 | CN 9 | 99.45 |
| Radiology, Nuclear Medicine and Imaging | 2021-2025 | 92 | CN 10 | 98.44 |
| Pulmonary and Respiratory Medicine | 2021-2025 | 198 | CN 31 | 98.53 |
| Surgery | 2021-2025 | 304 | CN 22 | 97.96 |
| Cancer Research | 2021-2025 | 54 | CN 25 | 97.86 |
| Pathology and Forensic Medicine | 2021-2025 | 123 | CN 8 | 97.13 |
| Cardiology and Cardiovascular Medicine | 2021-2025 | 520 | CN 14 | 92.32 |
| Advanced X-ray and CT Imaging | Lifetime | 269 | CN 9 | 98.47 |
| Radiation Dose and Imaging | Lifetime | 306 | CN 8 | 98.17 |
| Medical Imaging Techniques and Applications | Lifetime | 771 | CN 18 | 97.92 |
| Peptidase Inhibition and Analysis | Lifetime | 684 | CN 18 | 97.76 |
| Ultrasound and Hyperthermia Applications | Lifetime | 716 | CN 61 | 94.45 |
| Digital Radiography and Breast Imaging | Lifetime | 894 | CN 31 | 88.89 |
| Peptidase Inhibition and Analysis | 2021-2025 | 34 | CN 3 | 99.14 |
| Radiomics and Machine Learning in Medical Imaging | 2021-2025 | 192 | CN 53 | 98.19 |
| Cancer, Hypoxia, and Metabolism | 2021-2025 | 103 | CN 44 | 96.88 |
| RNA modifications and cancer | 2021-2025 | 575 | CN 389 | 95.47 |
| Ferroptosis and cancer prognosis | 2021-2025 | 453 | CN 376 | 94.09 |
| Extracellular vesicles in disease | 2021-2025 | 473 | CN 288 | 93.52 |
| Medical Imaging Techniques and Applications | 2021-2025 | 543 | CN 101 | 94.03 |
| Immune Cell Function and Interaction | 2021-2025 | 974 | CN 215 | 91.18 |
| Cancer, Lipids, and Metabolism | 2021-2025 | 509 | CN 190 | 89.07 |
| Lung Cancer Diagnosis and Treatment | 2021-2025 | 940 | CN 209 | 92.38 |
| Cardiac Ischemia and Reperfusion | 2021-2025 | 158 | CN 44 | 85.34 |
| Inflammatory Biomarkers in Disease Prognosis | 2021-2025 | 449 | CN 184 | 81.86 |
| Adrenal and Paraganglionic Tumors | 2021-2025 | 444 | CN 42 | 86.06 |
| Ubiquitin and proteasome pathways | 2021-2025 | 996 | CN 423 | 81.00 |
| Protease and Inhibitor Mechanisms | 2021-2025 | 259 | CN 77 | 79.22 |
| Amyloidosis: Diagnosis, Treatment, Outcomes | 2021-2025 | 798 | CN 24 | 78.31 |
| Cancer Mechanisms and Therapy | 2021-2025 | 970 | CN 431 | 71.53 |
| Spinal Dysraphism and Malformations | 2021-2025 | 568 | CN 64 | 69.23 |
| Flow Measurement and Analysis | 2021-2025 | 604 | CN 275 | 59.47 |
| Sirtuins and Resveratrol in Medicine | 2021-2025 | 966 | CN 335 | 53.58 |